Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vanda Pharmaceuticals Inc (VNDA) Valuation Multiples
Vanda Pharmaceuticals (VNDA) trades at 1.0x sales and 1.2x book value. Its P/S of 1.0x is below its 5-year median of 1.5x. Its forward P/E is 103.1x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 103.1x |
| Price to sales | 1.0x |
| Price to book | 1.2x |
| PEG | N/A |
| FCF yield | -60.8% |
Historical Medians
Against its 10-year medians, its P/S is 58.3% below 2.4x and its P/B is 20.0% below 1.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.0x | 1.5x | 2.4x |
| P/B | 1.2x | 0.7x | 1.5x |
Valuation History
Over the 6 of the 10 year ends shown that have a P/E, its P/E ranged from 7.0x in 2019 to 80.5x in 2023. 2023 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $8.82 | N/A | 2.4x | 1.6x |
| 2024 | $4.79 | N/A | 1.4x | 0.5x |
| 2023 | $4.22 | 80.5x | 1.3x | 0.4x |
| 2022 | $7.39 | 61.6x | 1.6x | 0.8x |
| 2021 | $15.69 | 27.1x | 3.3x | 1.8x |
| 2020 | $13.14 | 25.8x | 2.9x | 1.6x |
| 2019 | $16.41 | 7.0x | 3.9x | 2.2x |
| 2018 | $26.13 | 35.3x | 7.0x | 5.2x |
| 2017 | $15.20 | N/A | 4.1x | 5.2x |
| 2016 | $15.95 | N/A | 4.7x | 5.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VNDA
What is VNDA's forward P/E ratio?
Vanda Pharmaceuticals has a forward P/E ratio of 103.1x.
Is VNDA stock overvalued?
GNG's valuation label for VNDA is Undervalued.
What is VNDA's price to sales ratio?
Vanda Pharmaceuticals has a price to sales ratio of 1.0x.
VNDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts